Advancing Synovial Sarcoma Care: Exploring Innovations in Targeted Therapies - Episode 5
Key Differences in T-Cell Response Therapy vs CAR T Therapy
A panelist discusses how T-cell receptor (TCR) therapy offers potential advantages over chimeric antigen receptor (CAR) T therapy in solid tumors due to its ability to recognize intracellular antigens through human leukocyte antigen (HLA) presentation and its generally better safety profile with lower cytokine release syndrome rates, though TCR therapy faces its own challenges, including HLA restriction and potential cross-reactivity risks.
Video content above is prompted by the following:
- What are the key differences between TCR technology vs CAR T technology in this space? (Focusing on the differences in safety profiles seen in TCR and the ability to work well in solid tumors where CAR T has struggled)
Related Content:
